

ESG REPORT 2025

LARUS Pharma_{srl}

Annual summary | January–December 2025

LARUS Pharma srl



Total emissions:

13,085

kg CO₂ eq



Scope 1:

85.2%



Change vs 2024:

-1.3%



ENVIRONMENTAL

- Total Scope 1 + Scope 2 emissions: 13,085 kg CO₂ eq
- Scope 1: 11,145 kg CO₂ eq (85.2%)
- Scope 2: 1,940 kg CO₂ eq (14.8%)
- Change compared to 2024: -169 kg CO₂ eq (-1.3%)
- Reduction mainly linked to lower natural gas consumption
- Continued attention to materials, packaging and product responsibility

EMISSIONS BREAKDOWN



● **Scope 1**
85.2%

● **Scope 2**
14.8%



SOCIAL

- People-centered approach, quality of relationships and responsibility towards stakeholders
- Inclusive, safe working environment focused on wellbeing
- Golgi19 2025 seminar: "ISO 9001 as a driver of efficiency and sustainability"
- Training path on quality, process management and operational sustainability
- ISO 9001 and Halal certifications confirmed
- Full ISO 9001 renewal expected in 2026



GOVERNANCE

- Continuity of the management model and stable oversight of decision-making processes
- Code of Ethics and Conduct as a reference for integrity and accountability
- Assessment of an update and greater formalization of the Code of Ethics
- Compliance policy, internal audits and periodic checks
- Governance as a foundation for integrating sustainability into corporate decisions



2026 OBJECTIVES

- Continue monitoring Scope 1 and Scope 2
- Gradually assess the extension of reporting to Scope 3
- Improve the quality of environmental and product data
- Prepare for the future Digital Product Passport
- Strengthen dialogue with suppliers, customers and stakeholders
- Consolidate quality, sustainability and continuous improvement